Generalised demodicosis in dogs, clinical perspective

Shipstone, Michael A.

doi:10.1111/j.1751-0813.2000.tb11741.x

Cited by 36 publications

(47 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They may occur in small numbers as part of the normal fauna of the canine skin and can also be found in healthy dogs (Shipstone 2000;Scott et al 2001). Demodex mites spend their entire life cycle on the skin and are transmitted from the bitch to the nursing puppies within the first days after birth (Gaafer and Greeve 1966;Scott et al 2001).…”

Section: Introductionmentioning

confidence: 95%

“…It is believed that the disease results from the inability of the host to regulate mite numbers, rather than from an increase in the virulence of the mites. There is evidence suggesting that excessive proliferation of the Demodex mites may be due to an underlying genetic or immunological disorder in the affected dogs Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study >> and that the tendency to develop demodicosis has a hereditary basis (Shipstone 2000;Scott et al 2001).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot–on in the treatment of generalized demodicosis in dogs: results of a European field study

Heine

Krieger

Dumont³

et al. 2005

Parasitol Res

View full text Add to dashboard Cite

Efficacy and safety of the test product imidacloprid 10%+moxidectin 2.5% spot on (Advocate, Advantage multi) in the treatment of canine generalized demodicosis were evaluated in a multi-centre, controlled, randomized, blinded field study in Albania, France, and Germany. The study was conducted according to a non-inferiority design to demonstrate that the efficacy of the test product is not inferior to that of a control product containing milbemycin oxime (Interceptor, tablets for oral application). Of the 72 dogs enrolled, all of which expressed clinical signs of generalized demodicosis, 63 completed the study. Of these, 30 dogs were treated 2-4 times, at 4-week intervals, with the test product at the recommended dose of at least 0.1 ml/kg body weight. Thirty-three dogs were treated daily for two to four periods of 4 weeks with the control product according to label instructions (0.5-1 or 1-2 mg/kg body weight). Presence of mites in deep skin scrapings and clinical improvement were assessed 3-6 times at each inspection at 4-week intervals. Treatment was discontinued in dogs negative for mites on two subsequent examinations 4 weeks apart or at the last examination on day 84. At the end of the trial, dogs in both groups showed a similar clinical improvement. No Demodex mites were detected in 26 of 30 dogs treated with imidacloprid/moxidectin and in 29 of 33 dogs treated with milbemycin oxime. Statistical evaluation confirmed that the efficacy of the test product in the treatment of generalized canine demodicosis was not inferior to that of milbemycin oxime.

show abstract

Section: Introductionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 98%

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot–on in the treatment of generalized demodicosis in dogs: results of a European field study

Heine

Krieger

Dumont³

et al. 2005

Parasitol Res

View full text Add to dashboard Cite

show abstract

“…He also asserted that many more species would certainly be present, and that D. canis in some races of dogs gives rise to very severe pathological reactions which, when complicated by a bacterial infection, may even lead to death. Shipstone (2000) mentions that three species of Demodex mites have been reported on dogs and that although all three have been implicated in the aetiology of demodectic mange, D. canis is the most common cause of this disease. Small numbers of Demodex spp.…”

Section: Introductionmentioning

confidence: 99%

“…The localised manifestation usually occurs in young dogs (< 2 years old) and is characterised by discrete patches of alopecia and erythema and generally resolves spontaneously (Paradis 1999). Generalised demodectic mange may develop from the localised condition or occur in older animals, in which it is often associated with an immunosuppressive disease (Shipstone 2000). However, some authors believe that immunosuppression is induced by the parasite, or the host's reaction to it, and that it therefore follows rather than precedes the clinical manifestation of generalised demodicosis (Barriga et al 1992).…”

Section: Introductionmentioning

confidence: 99%

Comparative Efficacy and Safety of Two Treatment Regimens with a Topically Applied Combination of Imidacloprid and Moxidectin (Advocate®) against Generalised Demodicosis in Dogs

et al. 2009

View full text Add to dashboard Cite

This laboratory study compared the efficacy of two treatment regimens using an imidacloprid (10%)/moxidectin (2.5%) topical formulation (Advocate, Bayer) on dogs with generalised demodicosis. Sixteen dogs were randomly allocated to two equal groups. One group was treated at 28-day intervals for 12 weeks and the second group at weekly intervals for 15 weeks. Mite numbers were estimated and demodectic lesions were evaluated on each dog before treatment and at approximately 28-day intervals thereafter. Consistently greater reduction in mite numbers was recorded for the weekly treatment regimen. Dogs treated at weekly intervals exhibited markedly fewer clinical signs and greater hair regrowth and weight gain than those treated at 28-day intervals. To assess the safety of a weekly treatment interval in dogs, a study was done in which the investigational compound was administered at weekly intervals at five times the recommended dose for a period of 16 consecutive weeks. Apart from transient erythema at the site of administration in one dog and scaliness of the skin in another, no clinical signs of toxicity could be observed. Assessment of 27 blood parameters indicated that only basophils were outside the reference values on days +13 and +69, during the safety trial period.

show abstract

“…Use of ivermectins in dogs is not few in number (off-label treatments available). Ivermectins have been used for the treatment of demodicosis and flariasis in dogs (Shipstone 2000).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of eprinomectin against Toxacara canis in dogs

et al. 2007

View full text Add to dashboard Cite

This study was made to investigate efficacy of eprinomectin against to Toxocara canis in dogs. In the study, 20 stray dogs naturally infected with T. canis were divided into two groups as treatment (ten dogs) and control (ten dogs). Eprinomectin (100 microg/kg, Eprinex 250 ml) was given to treatment group dogs orally, and eggs per gram were determined in the faeces on the day of pre-treatment and the second, fourth, sixth, eighth and tenth days of post-treatment. No side effects associated with nervous, respiratory, gastrointestinal systems and some haematological parameters were observed. In conclusion, eprinomectin was determined to be 100% effectual against T. canis.

show abstract

Generalised demodicosis in dogs, clinical perspective

Cited by 36 publications

References 4 publications

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot–on in the treatment of generalized demodicosis in dogs: results of a European field study

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot–on in the treatment of generalized demodicosis in dogs: results of a European field study

Comparative Efficacy and Safety of Two Treatment Regimens with a Topically Applied Combination of Imidacloprid and Moxidectin (Advocate®) against Generalised Demodicosis in Dogs

Efficacy of eprinomectin against Toxacara canis in dogs

Contact Info

Product

Resources

About